Methods for the Administration of EDAR Pathway Modulators in Mice.
Détails
Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
Accès restreint UNIL
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
ID Serval
serval:BIB_7E7970A5AB18
Type
Partie de livre
Sous-type
Chapitre: chapitre ou section
Collection
Publications
Institution
Titre
Methods for the Administration of EDAR Pathway Modulators in Mice.
Titre du livre
The TNF Superfamily
Editeur
Springer
ISSN
1940-6029 (Electronic)
ISSN-L
1064-3745
Statut éditorial
Publié
Date de publication
2021
Peer-reviewed
Oui
Volume
2248
Série
Methods in molecular biology
Pages
167-183
Langue
anglais
Résumé
Genetic deficiency of ectodysplasin A (EDA) causes X-linked hypohidrotic ectodermal dysplasia, a congenital condition characterized by the absence or abnormal formation of sweat glands, teeth, and several skin appendages. Stimulation of the EDA receptor (EDAR) with agonists in the form of recombinant EDA or anti-EDAR antibodies can compensate for the absence of Eda in a mouse model of Eda deficiency, provided that agonists are administered in a timely manner during fetal development. Here we provide detailed protocols for the administration of EDAR agonists or antagonists, or other proteins, by the intravenous, intraperitoneal, and intra-amniotic routes as well as protocols to collect blood, to visualize sweat gland function, and to prepare skulls in mice.
Mots-clé
Animals, Animals, Newborn, Disease Models, Animal, Drug Administration Routes, Ectodermal Dysplasia/drug therapy, Ectodermal Dysplasia/genetics, Ectodermal Dysplasia/metabolism, Edar Receptor/genetics, Edar Receptor/metabolism, Mice, Phenotype, Recombinant Proteins/administration & dosage, Signal Transduction/drug effects, Treatment Outcome, Amniotic fluid, EDAR signaling, Ectodermal dysplasia, Protein replacement therapy, Route of administration
Pubmed
Web of science
Création de la notice
23/11/2020 14:57
Dernière modification de la notice
12/04/2024 7:45